Mechanisms of skin fibrosis in systemic sclerosis

Journal of Dermatology

Volumn 37, Issue 1, 2010, Pages 11-25

  Jinnin, Masatoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Collagen; Extracellular matrix; Transcription factors

Indexed keywords

COLLAGEN TYPE 1; COLLAGENASE; CYTOKINE; MATRIX METALLOPROTEINASE; SMAD PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

AUTOCRINE EFFECT; COLLAGEN SYNTHESIS; DERMIS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; SKIN CULTURE; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; UPREGULATION;

COLLAGEN; COLLAGENASES; CYTOKINES; FIBROBLASTS; FIBROSIS; HUMANS; METALLOENDOPEPTIDASES; SCLERODERMA, SYSTEMIC; SKIN; SMAD PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 75649096395     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00738.x     Document Type: Review

References (141)

1. Byers PH. Collagens: building blocks at the end of the development time. Clin Genet 2000 58: 270 279.
2. Holmes DF, Watson RB, Steinmann B, Kadler KE. Ehlers-Danlos syndrome type VIIB. Morphology of type I collagen fibrils formed in vivo and in vitro is determined by the conformation of the retained N-propeptide. J Biol Chem 1993 268: 15758 15765.
3. Widom RL. Regulation of matrix biosynthesis and degradation in systemic sclerosis. Curr Opin Rheumatol 2000 12: 534 539.
4. Uitto J, Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 2001 24: S60 S69.
5. Ghosh AK. Factors Involved in the Regulation of Type I Collagen Gene Expression: implication in Fibrosis. Exp Biol Med 2002 227: 301 314.
6. Ihn H. The role of TGF-β signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp 2002 50: 325 331.
7. Abraham D. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology 2008 47: v8 v9.
8. Duncun MR, Berman B. Differential regulation of collagen, glycosaminoglycan, fibronectin and collagenase activity production in cultured human adult dermal fibroblasts by interleukin 1α and β and tumor necrosis factor-α and β. J Invest Dermatol 1989 92: 699 706.
9. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix protein in response to interleukin 4. J Clin Invest 1992 90: 1479 1485.
10. Rutherford RB, Ross R. Platelet factors stimulate fibroblasts and smooth muscle cells quiescent in plasma serum to proliferate. J Cell Biol 1976 69: 196 203.
11. Cohen P, Carpenter G. Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci USA 1975 72: 1317 1321.
12. Trojanowska M, LeRoy EC, Eckes B, Krieg T. Pathogenesis of fibrosis: type I collagen and the skin. J Mol Med 1998 76: 266 274.
13. Jimenez SA, Gaidarova S, Saitta B et al. Role of protein kinase C-δ in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001 108: 1395 1403.
14. Korn JH. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1989 1: 479 484.
15. Mauch C, Krieg T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 1990 16: 93 107.
16. Mauch C, Kozlowska E, Eckes B, Krieg T. Altered regulation of collagen metabolism in scleroderma fibroblasts grown within three-dimensional collagen gels. Exp Dermatol 1992 1: 185 190.
17. Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts: increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996 39: 1338 1346.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988 15: 202 206.
19. Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med 2001 33: 7 21.
20. Inkinen K, Turakainen H, Wolff H, Ahonen J. Cloning of cDNA for rat pro α1(V) collagen mRNA. Expression patterns of type I, type III and type V collagen genes in experimental granulation tissue. Connect Tissue Res 1999 40: 209 220.
21. Hulmes DJ. Building collagen molecules, fibrils, and suprafibrillar structures. J Struct Biol 2002 137: 2 10.
22. Ono S, Imai T, Shimizu N, Nakayama M, Yamano T, Tsumura M. Serum markers of type I collagen synthesis and degradation in amyotrophic lateral sclerosis. Eur Neurol 2000 44: 49 56.
23. Bornstein P, Sage H. Regulation of collagen gene expression. Prog Nucleic Acid Res Mol Biol 1989 37: 67 106.
24. Ramirez F, Bernard M, Chu ML et al. Isolation and characterization of the human fibrillar collagen genes. Ann NY Acad Sci 1985 460: 117 129. (Pubitemid 16074813)
25. Retief E, Parker MI, Retief AE. Regional chromosome mapping of human collagen genes α2 (I) and α1 (I) (COLIA2 and COLIA1). Hum Genet 1985 69: 304 308.
26. Chu ML, de WetW, Bernard M et al. Human pro-α1 (I) collagen gene structure reveals evolutionary conservation of a pattern of introns and exons. Nature 1984 310: 337 340.
27. de WetWJ, Chu ML, Prockop DJ. The mRNAs for the pro-α1(I) and pro-α2(I) chains of Type I procollagen are translated at the same rate in normal human fibroblasts and in fibroblasts from two variants of osteogenesis imperfecta with altered steady-state ratios of the two mRNAs. J Biol Chem 1983 258: 14385 14389.
28. Chu ML, de WetW, Bernard M, Ramirez F. Fine structural analysis of the human pro-α1 (I) collagen gene. Promoter structure, AluI repeats, and polymorphic transcripts. J Biol Chem 1985 260: 2315 2320.
29. Dickson LA, de WetW, Di LibertoM, Weil D, Ramirez F. Analysis of the promoter region and the N-propeptide domain of the human pro α2(I) collagen gene. Nucleic Acids Res 1985 13: 3427 3438.
30. Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K. Potential regulatory elements of the constitutive up-regulated α2(I) collagen gene in scleroderma dermal fibroblasts. Biochem Biophys Res Commun 2006 343: 904 909.
31. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. J Invest Dermatol 1999 112: 49 57.
32. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004 113: 253 264.
33. Zhao J, Shi W, Wang YL et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002 282: L585 L593.
34. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. Ets1 is an effector of the transforming growth factor β (TGF-β) signaling pathway and an antagonist of the profibrotic effects of TGF-β. J Biol Chem 2002 277: 20399 20408.
35. Ihn H, Tamaki K. Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. Arthritis Rheum 2000 43: 2240 2247.
36. Tamaki T, Ohnishi K, Hartl C, LeRoy EC, Trojanowska M. Characterization of a GC-rich region containing Sp1 binding site(s) as a constitutive responsive element of the α2(I) collagen gene in human fibroblasts. J Biol Chem 1995 270: 4299 4304.
37. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001 276: 20839 20848.
38. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009 29: 425 434.
39. Luchetti MM, Paroncini P, Majlingovà P et al. Characterization of the c-Myb-responsive region and regulation of the human type I collagen α2 chain gene by c-Myb. J Biol Chem 2003 278: 1533 1541.
40. Piccinini G, Golay J, Flora A et al. C-myb, but not B-myb, upregulates type I collagen gene expression in human fibroblasts. J Invest Dermatol 1999 112: 191 196.
41. Trojanowska M, Wu LT, LeRoy EC. Elevated expression of c-myc proto-oncogene in scleroderma fibroblasts. Oncogene 1988 3: 477 481.
42. Yang BS, Geddes TJ, Pogulis RJ, de CrombruggheB, Freytag SO. Transcriptional suppression of cellular gene expression by c-Myc. Mol Cell Biol 1991 11: 2291 2295.
43. Goldman PS, Tran VK, Goodman RH. The multifunctional role of the co-activator CBP in transcriptional regulation. Recent Prog Horm Res 1997 52: 103 119.
44. Wotton D, Lo RS, Lee S, Massague J. A Smad transcriptional corepressor. Cell 1999 97: 29 39.
45. Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation. Genes Dev 1998 12: 2153 2163.
46. Janknecht R, Wells NJ, Hunter T. TGF-β-stimulated cooperation of Smad proteins with the coactivators CBP/p300. Genes Dev 1998 12: 2114 2119.
47. Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF. TGF-β-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol Biol Cell 1998 9: 3309 3319.
48. Grant PA, Sterner DE, Duggan LJ, Workman JL, Berger SL. The SAGA unfolds: convergence of transcription regulators in chromatin-modifying complexes. Trends Cell Biol 1998 8: 193 197.
49. Ghosh AK, Yuan W, Mori Y, Varga J. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 2000 19: 3546 3555.
50. Ghosh AK, Varga J. Transcrptional coactivators p300/CBP and Type I collagen gene expression. Curr Sci 2003 85: 155 161.
51. Bhattacharyya S, Ghosh AK, Pannu J et al. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor β. Arthritis Rheum 2005 52: 1248 1258.
52. Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology 2006 45: 157 165.
53. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor b signaling. Proc Natl Acad Sci USA 1999 96: 12442 12447.
54. Akiyoshi S, Inoue H, Hanai J et al. c-Ski acts as a transcriptional co-repressor in transforming growth factor-β signaling through interaction with Smads. J Biol Chem 1999 274: 35269 35277.
55. Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K. Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor β signaling in scleroderma fibroblasts. Arthritis Rheum 2007 56: 1694 1705.
56. Ihn H. Autocrine TGF-β signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008 49: 103 113.
57. McDonnell S, O'Connor A, Murray D, Lynch CC. Matrix metalloproteinases. In: Genazzani AR ed. Hormone Replacement Therapy and Cancer: The Current Status of Research and Practice. London, UK: Informa Health Care, 2002 17 24.
58. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001 17: 463 516.
59. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res 1993 28: 500 510.
60. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003 253: 269 285.
61. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993 4: 197 250.
62. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore Curr Opin Cell Biol 2001 (Oct 13 (5 534 540.
63. Wang Y, Rosen H, Madtes DK et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem 2007 282: 31826 31834.
64. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004 49: 187 198.
65. Murawaki Y, Ikuta Y, Kawasaki H. Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 1999 281: 109 120.
66. Parsons SL, Watoson SA, Brown PD, Collins HM, Steele RJC. Matrix metalloproteinases. Br J Surg 1997 84: 160 166.
67. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997 74: 111 122.
68. Schuppan D, Freitag T. Fistulising Crohn's disease: MMPs gone away. Gut 2004 53: 622 624.
69. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008 27: 679 690.
70. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997 289: 567 572.
71. Young-Min SA, Beeton C, Laughton R et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001 60: 846 851.
72. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003 120: 542 547.
73. Nishijima C, Hayakawa I, Matsushita T et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004 138: 357 363.
74. Holmbeck K, Bianco P, Caterina J et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999 99: 81 92.
75. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000 279: G245 G249.
76. Watanabe T, Niioka M, Hozawa S et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol 2000 33: 224 235.
77. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007 22: 2838 2848.
78. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001 89: 201 210.
79. Corbel M, Caulet-Maugendre S, Germain N, Molet S, Lagente V, Boichot E. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. J Pathol 2001 193: 538 545.
80. Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol 2004 49: 199 202.
81. Gearing AJH, Beckett P, Christodoulou M et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994 370: 555 557.
82. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol 1998 161: 3340 3346.
83. Narayanan AS, Page RC, Swanson J. Collagen synthesis by human fibroblasts: regulation by transforming growth factor-β in the presence of other inflammatory mediators. Biochem J 1989 260: 463 469.
84. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 1994 180: 1587 1590.
85. Massague J. TGF-β signal tansduction. Ann Rev Biochem 1998 67: 753 791.
86. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor-β1 by plasmin. J Cell Biol 1990 110: 1361 1367.
87. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K. Increased expression of integrin αvβ5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006 168: 499 510.
88. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993 122: 923 932.
89. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000 11: 59 69.
90. Mu D, Cambier S, Fjellbirkeland L et al. The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J Cell Biol 2002 157: 493 507.
91. Wrana JL, Attisano L, Weisser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994 370: 341 347.
92. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-β responses. Cell 1998 95: 737 740.
93. Jinnin M, Ihn H, Yamane K, Mimura Y, Asano Y, Tamaki K. α2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res 2005 33: 1337 1351.
94. Hayashi H, Abdollah S, Qiu Y et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997 89: 1165 1173.
95. Nakao A, Afrakhte M, Moren A et al. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature 1997 389: 631 635.
96. Kavsak P, Rasmussen RK, Causing CG et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol Cell 2000 6: 1365 1375.
97. Verrecchia F, Mauviel A. Transforming growth factor-β and fibrosis. World J Gastroenterol 2007 13: 3056 3062.
98. Hasegawa M, Sato S, Takehara K. Augmented production of transforming growth factor-β by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res 2004 296: 89 93.
99. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001 44: 474 480.
100. Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts. Biochem Biophys Res Commun 1992 187: 45 50.
101. Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K. Involvement of αvβ5 integrin in the establishment of autocrine TGF-β signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006 126: 1761 1769.
102. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005 52: 2897 2905.
103. Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor β type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999 29: 1730 1738.
104. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998 110: 47 51.
105. Pannu J, Gore-Hyer E, Yamanaka M et al. An increased transforming growth factor β receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 2004 50: 1566 1577.
106. Massague J. Transforming growth factor-β family. Ann Rev Cell Biol 1990 6: 597 641.
107. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor β the answer Arthritis Rheum 1989 32: 817 825.
108. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995 270: 3423 3428.
109. Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C. Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 2006 20: 562 564.
110. De WinterP, Leoni P, Abraham D. Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein. Growth Factors 2008 26: 80 91.
111. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993 4: 637 645.
112. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996 107: 404 411.
113. Chujo S, Shirasaki F, Kawara S et al. Connective tissue growth factor causes persistent proα2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 2005 203: 447 456.
114. Ikawa Y, Ng PS, Endo K et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-β-induced mouse fibrosis. J Cell Physiol 2008 216: 680 687.
115. Takehara K. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 2003 30: 755 759.
116. Chujo S, Shirasaki F, Kondo-Miyazaki M, Ikawa Y, Takehara K. Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol 2009 220: 189 195.
117. Sato S, Nagaoka T, Hasegawa M et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000 27: 149 154.
118. Igarashi A, Nashiro K, Kikuchi K et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995 (Aug 105 (2 280 284.
119. Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001 13: 505 511.
120. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001 276: 10594 10601.
121. Fonseca C, Lindahl GE, Ponticos M et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007 357: 1210 1220.
122. Kirk TZ, Mayes MD. IL-1 rescues scleroderma myofibroblasts from serum-starvation-induced cell death. Biochem Biophys Res Commun 1999 255: 129 132.
123. Kawaguchi Y, McCarthy SA, Watkins SC, Wright TM. Autocrine activation by interleukin 1α induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004 31: 1946 1954.
124. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999 103: 1253 1260.
125. Hu B, Wang S, Zhang Y, Feghali CA, Dingman JR, Wright TM. A nuclear target for interleukin-1α: interaction with the growth suppressor necdin modulates proliferation and collagen expression. Proc Natl Acad Sci USA 2003 100: 10008 10013.
126. Heino J, Heinonen T. Interleukin-1β prevents the stimulatory effect of transforming growth factor-β on collagen gene expression in human skin fibroblasts. Biochem J 1990 71: 827 830.
127. Honda A, Abe R, Makino T et al. Interleukin-1β and macrophage migration inhibitory factor (MIF) in dermal fibroblasts mediate UVA-induced matrix metalloproteinase-1 expression. J Dermatol Sci 2008 49: 63 72.
128. Postlethwaite AE, Lachman LB, Kang AH. Induction of fibroblast proliferation by interleukin-1 derived from human monocytic leukemia cells. Arthritis Rheum 1984 27: 995 1001.
129. Morgan JG, Dolganov GM, Robbins SE, Hinton LM, Lovett M. The selective isolation of novel cDNAs encoded by the regions surrounding the human interleukin 4 and 5 genes. Nucleic Acids Res 1992 20: 5173 5179.
130. Zurawski SM, Vega F Jr., Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993 12: 2663 2670.
131. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997 24: 328 332.
132. Needleman BW, Fredrick M, Wigley M, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992 35: 67 72.
133. Salmon-Ehr V, Serpier H, Nawrocki B et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 1996 (Jul 132 (7 802 806.
134. Jinnin M, Ihn H, Yamane K, Tamaki K. Interleukin-13 stimulates the transcription of the human α2(I) collagen gene in human dermal fibroblasts. J Biol Chem 2004 279: 41783 41791.
135. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000 292: 988 994.
136. Kolodsick JE, Toews GB, Jakubzick C et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004 172: 4068 4076.
137. Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K. IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase dependent pathway. J Immunol 2002 168: 1895 1902.
138. Morelli S, Ferri C, Polettini E et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995 99: 255 260.
139. Shi-Wen X, Denton CP, Dashwood MR et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001 116: 417 425.
140. Shi-Wen X, Chen Y, Denton CP et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004 (Jun 15 (16 2707 2719.
141. Kawaguchi Y, Takagi K, Hara M et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004 (Jan 50 (1 216 226.